Close Menu

NEW YORK (GenomeWeb) – Epigenomics today reported a nearly 5 percent decline in first quarter revenues, primarily due to the conclusion of agreements with licensing partners for the sale of its products.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.